Unknown

Dataset Information

0

Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings.


ABSTRACT: PSMA PET imaging was originally used to assess biochemical recurrence of prostate cancer (PCa), but its clinical use was promptly extended to detection, staging and therapy response assessment. The expanding use of PSMA PET worldwide has also revealed PSMA ligand uptake in diverse nonprostatic diseases, which raised questions about the specificity of this imaging modality. Although not very common initially, a growing number of pathologies presenting PSMA uptake on PET have been reported in the last few years, and a proper interpretation of PSMA PET imaging findings suddenly became challenging and, to some extent, confusing. Compared to cytoplasmic PSMA expression in nonprostatic cells, the molecular features of apical PSMA expression in PCa cells can help to distinguish these various conditions. Correlations of imaging findings to patient history, to the expected pattern of disease spread and mainly to computed tomography (CT) and/or magnetic resonance imaging (MRI) characteristics will reinforce the distinction of lesions that are more likely related to PCa from those that could lead to an incorrect diagnosis. The overall benefits of endothelial PSMA expression, which is associated with the neovasculature of malignant neoplasms, will be highlighted, stating the potential use of PSMA ligand uptake as a theranostic tool. This review aims to cover the collection of nonprostatic diseases, including benign and malignant tumors, in a didactic approach according to disease etiology, with discussion of bone-related conditions and inflammatory and infectious processes.

SUBMITTER: de Galiza Barbosa F 

PROVIDER: S-EPMC7071711 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings.

de Galiza Barbosa Felipe F   Queiroz Marcelo Araujo MA   Nunes Rafael Fernandes RF   Costa Larissa Bastos LB   Zaniboni Elaine Caroline EC   Marin José Flavio Gomes JFG   Cerri Giovanni Guido GG   Buchpiguel Carlos Alberto CA  

Cancer imaging : the official publication of the International Cancer Imaging Society 20200314 1


PSMA PET imaging was originally used to assess biochemical recurrence of prostate cancer (PCa), but its clinical use was promptly extended to detection, staging and therapy response assessment. The expanding use of PSMA PET worldwide has also revealed PSMA ligand uptake in diverse nonprostatic diseases, which raised questions about the specificity of this imaging modality. Although not very common initially, a growing number of pathologies presenting PSMA uptake on PET have been reported in the  ...[more]

Similar Datasets

| S-EPMC4999143 | biostudies-literature
| S-EPMC3934523 | biostudies-other
| S-EPMC3849093 | biostudies-literature
| S-EPMC8635528 | biostudies-literature
| S-EPMC2271083 | biostudies-other
| S-EPMC7964410 | biostudies-literature
| S-EPMC2843107 | biostudies-literature
| S-EPMC2440923 | biostudies-other
| S-EPMC8013129 | biostudies-literature
| S-EPMC6322287 | biostudies-literature